---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Access and distribution"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Access and distribution. Topics: Launch preparation and commercial infrastructure; Appointment of a Chief Commercial Officer; Commercialization plans in the United States, the European Union, and Asia-Pacific; Contract manufacturing, redundant supply chain, and distribution of investigational product; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/access-and-distribution"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Launch preparation and commercial infrastructure

> “The increase was primarily attributable to costs related to launch preparation efforts and an increase in personnel-related expenses for the quarter ended September 30, 2026, partially offset by severance and transaction costs related to the merger with ACELYRIN, Inc. and legal costs in the quarter ended September 30, 2025.”

Source: [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)

> “Given our stage of development, we do not yet have a fully established marketing or sales organization or commercial infrastructure; however, we have begun building foundational capabilities and intend to continue expanding the necessary sales, marketing and commercialization capabilities and infrastructure over time as our product candidates advance through clinical development and regulatory approval.”
> “Professional consulting services expenses increased by $0.4 million, to $8.4 million for the three months ended September 30, 2026, from $8.0 million for the three months ended September 30, 2025, primarily due to an increase in costs to support our launch preparation efforts, partially offset by legal expenses and other costs incurred in the prior year.”
> “procure manufacturing and supply chain capacity for our product candidates, including commercial manufacturing readiness and scale-up;”
> “take steps toward our goal of being an integrated biopharma company capable of supporting commercial activities, including establishing sales, marketing and distribution infrastructure;”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

> “With our fourth-quarter 2026 NDA submission firmly on track, our organization is focused on regulatory execution and building the foundation designed to bring this next-generation therapy to patients.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="topic-2.1.2.11-2"></a>

### Appointment of a Chief Commercial Officer

> “Jack Danilkowicz was appointed as Chief Commercial Officer bringing extensive experience successfully planning and executing commercial strategies at global biopharmaceutical companies.”

Source: [Alumis press release, year end 2024 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319xex99d1.htm)

<a id="topic-2.1.2.11-3"></a>

### Commercialization plans in the United States, the European Union, and Asia-Pacific

> “Given our stage of development, we have not yet established a full commercial organization or distribution capabilities.”
> “We have stage-appropriate commercial capabilities and we intend to build a commercial infrastructure to support sales of any approved products.”
> “In addition, we intend to commercialize our product candidates, if approved, in key markets in the United States, the European Union (“EU”) and APAC, either alone or with partners in order to maximize the worldwide commercial potential of our programs.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.11-4"></a>

### Contract manufacturing, redundant supply chain, and distribution of investigational product

> “We are in the process of implementing a redundant supply chain for envu API, drug product and critical raw material.”
> “Additional contract manufacturers are used to package, label, and distribute investigational drug products.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.11-5"></a>

### Distribution agreements and logistics required after approval

> “If approved for marketing by applicable regulatory authorities, our ability to generate revenue from our product candidates will depend on our ability to:”
> “establish and maintain agreements with wholesalers, distributors, pharmacies and group purchasing organizations on commercially reasonable terms;”
> “maintain a distribution and logistics network capable of product storage within our specifications and regulatory guidelines, and further capable of timely product delivery to commercial clinical sites; and”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

<a id="topic-2.1.2.11-6"></a>

### Expanded access policy

> “Currently, production of our investigational drugs is limited to accommodate participants in clinical trials and therefore, Alumis does not offer expanded access.”
> “As we are not currently accepting expanded access requests for our investigational drug, we do not have a procedure for making an expanded access request or contact information for such requests.”
> “Alumis may review and update this policy over time as more clinical data becomes available.”

Source: [Alumis expanded access policy page](https://www.alumis.com/patients/expanded-access/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
